https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-5472022-03-10 00:00:002022-03-10 00:00:00Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-03-08 / Expert Rev Vaccines 2022 Apr;21(4):513-531
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-03-08 / Expert Rev Vaccines 2022 Apr;21(4):513-5312022-03-08 00:00:002022-03-08 00:00:00A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-16 / Genes Immun 2022 Feb;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-15 / Leuk Lymphoma 2022 Jul;63(7):1733-1737
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-15 / Leuk Lymphoma 2022 Jul;63(7):1733-17372022-02-15 00:00:002022-02-15 00:00:00Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-04 / Curr Oncol 2022 Feb;29(2):881-8912022-02-04 00:00:002023-01-31 12:41:45Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):32022-01-24 00:00:002022-01-24 00:00:00Research progress on dendritic cell vaccines in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-19 / Genes Immun 2022 02;23(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-19 / Genes Immun 2022 02;23(1):1-112022-01-19 00:00:002022-01-19 00:00:00Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-07 / J Healthc Eng 2022;2022:2518847
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-07 / J Healthc Eng 2022;2022:25188472022-01-07 00:00:002022-01-07 00:00:00GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-353
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-3532022-01-06 00:00:002022-01-06 00:00:00Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)2022-01-01 00:00:002022-01-01 00:00:00Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
